Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of FerrlecitÂ® Injection by Sanofi Aventis] Based on Its Proprietary Technology
EWING, N.J., March 31, 2011 /PRNewswire/ — Navinta’s proprietary complex pharmaceutical ingredient, Sodium Ferric Gluconate as covered under Navinta’s US Patent 7,179,939 and US Drug Master File is a key component in the recent approval of GeneraMedix Inc.’s ANDA for Sodium Ferric Gluconate Complex in Sucrose Injection, 62.5 mg/5 mL.
The Navinta’s proprietary complex pharmaceutical ingredient technology provides a platform for preparation of complex injectable formulations of Iron drug products.
“We are pleased to see commercialization of our innovative complex pharmaceutical product,” said Dr. Mahendra Patel, Chief Executive Officer of Navinta, LLC. “Our work represents the culmination of many years of laboratory and drug development work. Navinta’s development pipe line targets several such complex molecules in their development portfolio.”
Navinta, LLC in Ewing, N.J. is a technology driven Pharmaceutical Company that focuses on novel routes of synthesis of new and existing drug molecules, complex pharmaceutical ingredients, novel formulations of liquid dosage form, novel oral dosage form, novel injectable dosage form and implantable drug delivery devices. Navinta has currently at least fifteen (15) patents granted or pending with the United States Patent and Trademark Office.
SOURCE Navinta LLC